DNA RNA and Cells

08 Oct 2020 TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based Immunotherapy Company
08 Oct 2020 Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
08 Oct 2020 OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases
08 Oct 2020 Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage™ Platform Targeting Multiple Cancers
08 Oct 2020 Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
07 Oct 2020 Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
07 Oct 2020 Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
06 Oct 2020 First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
06 Oct 2020 AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
06 Oct 2020 Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS® T Cell Therapy in Hepatocellular Carcinoma
06 Oct 2020 Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies
02 Oct 2020 bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)
02 Oct 2020 Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)
02 Oct 2020 Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
02 Oct 2020 Mesoblast Receives Complete Response Letter From the FDA for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
01 Oct 2020 Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
30 Sep 2020 Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product
29 Sep 2020 Orgenesis announces agreement to acquire Koligo Therapeutics, a leader in personalized cell therapies
29 Sep 2020 Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy
29 Sep 2020 Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis
29 Sep 2020 Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
29 Sep 2020 Celyad Oncology Announces Clinical Trial Collaboration to Evaluate CYAD-101 with KEYTRUDA® (pembrolizumab) in Patients with Microsatellite Stable mCRC
28 Sep 2020 Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
28 Sep 2020 Sarepta Therapeutics Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Functional Improvements 18-months After Administration
25 Sep 2020 OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up